Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.59 |
| ▸ | MMP2 | P08253 | 5/20 | 0.59 |
| ▸ | MMP9 | P14780 | 3/20 | 0.59 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.57 |
| ▸ | ACE | P12821 | 4/20 | 0.57 |
| ▸ | CPA1 | P15085 | 3/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.54 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.54 |
| ▸ | FPR2 | P25090 | 5/20 | 0.52 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533645 | 0.91 | PPARG (0.58) | MMEMMP2MMP9PPARGFPR2 | |
| SCHEMBL6250861 | 0.91 | PPARG (0.58) | MMEMMP2MMP9PPARGFPR2 | |
| SCHEMBL1533647 | 0.91 | PPARG (0.58) | MMEMMP2MMP9PPARGFPR2 | |
| SCHEMBL28789647 | 0.88 | PPARG (0.60) | MMEPPARGACEFPR2 | |
| SCHEMBL29166010 | 0.88 | PPARG (0.56) | MMEMMP2MMP9PPARGITGB1 | |
| SCHEMBL28789648 | 0.88 | PPARG (0.60) | MMEPPARGACEFPR2 | |
| SCHEMBL27509445 | 0.87 | ALDH1A1 (0.59) | MMEPPARGITGB1ITGA4FPR2 | |
| SCHEMBL27746696 | 0.87 | ALDH1A1 (0.59) | MMEPPARGITGB1ITGA4FPR2 | |
| SCHEMBL7100965 | 0.87 | PPARG (0.55) | MMEMMP9PPARGITGB1ITGA4 | |
| SCHEMBL9843176 | 0.87 | ADAMTS5 (0.57) | MMEMMP2PPARGFPR2ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030143664-A1 | Products of manufacture and processes for peptide synthesis | DIVERSA CORPORATION (US) | 2003-07-31 | — | — | US | claimed |
| EP-4389757-A2 | METHODS FOR PURIFYING ANTIBODIES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-26 | — | — | EP | disclosed |
| CN-118076632-A | Conditionally active proteins for neurodegenerative diseases | 生物蛋白有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4371996-A2 | METHODS FOR PURIFYING ANTIBODIES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-3510042-B1 | METHODS FOR PURIFYING ANTIBODIES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024102332-A1 | VACCINE COMPOSITIONS COMPRISING A NEOANTIGEN OF KRAS | HIMV LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024091513-A1 | BIOMIMETIC EXTRACELLULAR MATRIX NANOFIBERS ELECTROSPUN WITH CALRETICULIN | NEW YORK UNIVERSITY (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240109953-A1 | APOLIPOPROTEIN B (APOB) POLYPEPTIDES FOR BLOCKING ENDOTHELIAL CELL UPTAKE OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS | NEW YORK UNIVERSITY (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240100139-A1 | NEOANTIGENS AND USES THEREOF | BIONTECH US INC. | 2024-03-28 | — | — | US | disclosed |
| EP-3680000-B1 | METHODS FOR PURIFYING ANTIBODIES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-03-13 | — | — | EP | disclosed |
| WO-1996040927-A1 | ISOSPORA SUIS VACCINE | AMBICO, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0745095-A1 | PEPTIDES RECOGNIZED BY MELANOMA-SPECIFIC CYTOTOXIC LYMPHOCYTES, AND USES THEREFOR | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5508384-A | NEUROLEPTIC AGENTS WITH REDUCED SIDE EFFECTS | NEW YORK UNIVERSITY (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1995022561-A2 | PEPTIDES RECOGNIZED BY MELANOMA-SPECIFIC CYTOTOXIC LYMPHOCYTES, AND USES THEREFOR | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1995-08-24 | — | — | WO | disclosed |
| WO-1995020397-A1 | PHOSPHACAN, NUCLEIC ACIDS ENCODING THEREOF AND ANTIBODIES THERETO | NEW YORK UNIVERSITY (US) | 1995-08-03 | — | — | WO | disclosed |
| WO-1995013828-A1 | BENEFICIAL WOUND HEALING APPLICATIONS OF CALRETICULIN AND OTHER HYALURONAN-ASSOCIATED PROTEINS | NEW YORK UNIVERSITY (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995013291-A1 | NEURON-GLIA CELL ADHESION MOLECULE, NG-CAM, IN TREATMENT OF NERVE DAMAGE | NEW YORK UNIVERSITY (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1994003601-A9 | CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN | — | 1994-03-31 | — | — | WO | disclosed |
| WO-1994005695-A1 | POLYPEPTIDES OF G-COUPLED RECEPTOR PROTEINS, AND COMPOSITIONS AND METHODS THEREOF | NEW YORK UNIVERSITY (US) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994003601-A2 | CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN | NEW YORK UNIVERSITY (US) | 1994-02-17 | — | — | WO | disclosed |